Logo

People in the News: Paul Billings: May 7, 2014

May 08, 2014
Premium

Genome interpretation firm Omicia has hired Paul Billings as its new chief medical officer. Billings will also serve on the firm's scientific advisory board.

He comes to Omicia from Life Technologies, which was acquired by Thermo Fisher Scientific and where he was chief medical officer. Before that, Billings was chief scientific officer of the Genomic Medicine Institute at El Camino Hospital, and CEO of CELLective Dx Corporation. Billings is a genomics industry leader and has held executive-level positions at numerous top life sciences firms and organizations.

Filed under

Diagnostics
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.